Francisco Leon M.D., Ph.D.
Net Worth

Last updated:

What is Francisco Leon M.D., Ph.D. net worth?

The estimated net worth of Dr. Francisco Leon M.D., Ph.D. is at least $7,278,919 as of 13 Feb 2023. He has earned $3,057,919 from insider trading and has received compensation worth at least $4,221,000 in Provention Bio, Inc..

What is the salary of Francisco Leon M.D., Ph.D.?

Dr. Francisco Leon M.D., Ph.D. salary is $603,000 per year as Co-Founder & Chief Scientific Officer in Provention Bio, Inc..

How old is Francisco Leon M.D., Ph.D.?

Dr. Francisco Leon M.D., Ph.D. is 53 years old, born in 1972.

What stocks does Francisco Leon M.D., Ph.D. currently own?

As insider, Dr. Francisco Leon M.D., Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Provention Bio, Inc. (PRVB) Co-Founder & Chief Scientific Officer 1,573,000 $0 $0

What does Provention Bio, Inc. do?

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.

PRVB logo
PRVB
Provention Bio, Inc.

Francisco Leon M.D., Ph.D. insider trading

Provention Bio, Inc.

Dr. Francisco Leon M.D., Ph.D. has made 7 insider trades between 2018-2023, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 187,000 units of PRVB stock on 29 Dec 2022. As of 13 Feb 2023 he still owns at least 1,573,000 units of PRVB stock.

Transaction Date Security Shares Price per share Total value Source
Option
Stock Option (right to buy) 25,985 $2.5 $64,963
Option
Common Stock 25,985 $2.5 $64,963
Sale
Common Stock 25,985 $10.04 $260,941
Option
Stock Option (right to buy) 50,000 $2.5 $125,000
Option
Common Stock 50,000 $2.5 $125,000
Sale
Common Stock 50,000 $10.11 $505,600
Option
Common Stock 24,015 $2.5 $60,038
Option
Stock Option (right to buy) 24,015 $2.5 $60,038
Sale
Common Stock 24,015 $10.27 $246,586
Option
Stock Option (right to buy) 187,000 $2.5 $467,500
Option
Common Stock 187,000 $2.5 $467,500
Sale
Common Stock 187,000 $10.26 $1,918,620
Option
Common Stock 10,674 $2.5 $26,685
Option
Stock Option (right to buy) 10,674 $2.5 $26,685
Sale
Common Stock 10,674 $10 $106,740
Sale
Common Stock 375 $10 $3,750
Option
Stock Option (right to buy) 375 $2.5 $938
Option
Common Stock 375 $2.5 $938
Option
Common Stock 1,568 $2.5 $3,920
Sale
Common Stock 1,568 $10 $15,682
Option
Stock Option (right to buy) 1,568 $2.5 $3,920
Purchase
Common Stock 5,550 $7.24 $40,188
Purchase
Common Stock 2,000 N/A N/A
Purchase
Common Stock 2,000 N/A N/A
Purchase
Common Stock 10,000 N/A N/A
Purchase
Common Stock 2,000 N/A N/A
Purchase
Common Stock 1,450 N/A N/A
Purchase
Common Stock 2,500 N/A N/A
Purchase
Common Stock 10,000 N/A N/A
Purchase
Common Stock, par value $0.0001 per share 37,500 N/A N/A

Provention Bio key executives

Provention Bio, Inc. executives and other stock owners filed with the SEC: